Athira Pharma (NASDAQ:LONA) Cut to “Sell” at Wall Street Zen

Athira Pharma (NASDAQ:LONA) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday.

Several other research analysts also recently commented on LONA. Weiss Ratings began coverage on shares of Athira Pharma in a research note on Wednesday, February 11th. They issued a “sell (d-)” rating on the stock. Mizuho raised Athira Pharma from a “neutral” rating to an “outperform” rating and set a $10.00 target price on the stock in a research note on Thursday, February 19th. Finally, Cantor Fitzgerald initiated coverage on shares of Athira Pharma in a research report on Thursday. They set an “overweight” rating for the company. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Athira Pharma currently has a consensus rating of “Hold” and an average target price of $10.00.

Athira Pharma Trading Up 0.2%

Shares of LONA stock opened at $5.63 on Friday. Athira Pharma has a 12-month low of $2.20 and a 12-month high of $8.36.

Athira Pharma Company Profile

Athira Pharma, traded as LONA on the NASDAQ, is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapeutics intended to restore neuronal health and function in neurodegenerative and cognitive disorders. The company’s research approach centers on modulating pathways involved in synaptic repair and neurotrophic signaling to address underlying neuronal dysfunction rather than solely treating symptoms.

Athira’s lead investigational therapy is fosgonimeton (ATH-1017), a small-molecule candidate designed to potentiate hepatocyte growth factor (HGF)/MET pathway signaling with the aim of improving synaptic connectivity and cognitive performance in patients with conditions such as Alzheimer’s disease and related cognitive impairments.